NCT05459597Recruiting
Antiepileptic Drugs in Elderly Patients
Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients
Source: ClinicalTrials.gov · Last updated 15 Jul 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 4 Jul 2022
- Start date
- 1 Jan 2021
- Primary completion date
- 30 Mar 2028
- Lead sponsor
- Wei Zhao
- Diseases
- Epilepsy
- NCT number
- NCT05459597
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jan 2021 to the primary completion date, 30 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving other investigational drugs;
Other illness
- Patients with allergy to antiepileptic drugs;
Other
- Patients who are expected to die within 48 hours;
- Other factors that the researcher considers unsuitable for inclusion.
Who the study is looking for
- Age ≥65 years old;
- Diagnosed with epilepsy;
- Using antiepileptic drugs for treatment;
Age in the registry: 65 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wei Zhao Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.